SCHEMBL24937400

SCHEMBL24937400

CCn1nccc1C(=O)OC

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ L3MBTL1 Q9Y468 1/20 0.56
▸ RAB9A P51151 3/20 0.53
▸ NPC1 O15118 2/20 0.53
▸ MEN1 O00255 4/20 0.52
▸ KMT2A Q03164 4/20 0.52
▸ ALDH1A1 P00352 3/20 0.52
▸ SMN1; SMN2 Q16637 2/20 0.52
▸ MAPT P10636 2/20 0.52
▸ NPSR1 Q6W5P4 2/20 0.52
▸ HPGD P15428 1/20 0.52
▸ HTT P42858 2/20 0.50
▸ F2 P00734 1/20 0.48
▸ PLAU P00749 1/20 0.48
▸ KLKB1 P03952 1/20 0.48
▸ ELANE P08246 1/20 0.48
▸ ABL1 P00519 1/20 0.43
▸ SRC P12931 1/20 0.43
▸ FLT1 P17948 1/20 0.40
▸ KDR P35968 1/20 0.40
▸ LMNA P02545 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30829495 0.86 F2 (0.46) L3MBTL1RAB9ANPC1MEN1KMT2A
SCHEMBL7056155 0.86 F2 (0.48) L3MBTL1RAB9ANPC1MEN1KMT2A
SCHEMBL7056151 0.86 F2 (0.48) L3MBTL1RAB9ANPC1MEN1KMT2A
SCHEMBL1431721 0.84 RAB9A (0.50) L3MBTL1RAB9ANPC1MEN1KMT2A
SCHEMBL570181 0.84 RAB9A (0.49) L3MBTL1RAB9ANPC1MEN1KMT2A
SCHEMBL31460083 0.84 F2 (0.47) L3MBTL1RAB9ANPC1MEN1KMT2A
SCHEMBL6258525 0.83 F2 (0.43) L3MBTL1RAB9ANPC1MEN1KMT2A
SCHEMBL20660787 0.83 F2 (0.46) L3MBTL1RAB9ANPC1MEN1KMT2A
SCHEMBL24875516 0.81 F2 (0.44) L3MBTL1RAB9ANPC1MEN1KMT2A
SCHEMBL796641 0.80 F2 (0.43) L3MBTL1RAB9ANPC1MEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12595249-B2 Aryl ether-substituted heterocyclic compounds as glpir agonists MINDRANK AI LTD. (CN) 2026-04-07 — — US disclosed
US-12497384-B2 Aryl ether-substituted heterocyclic compounds as GLP1R agonists MINDRANK AI LTD. (CN) 2025-12-16 — — US disclosed
US-20250304553-A1 ARYL ETHER-SUBSTITUTED HETEROCYCLIC COMPOUNDS AS GLP1R AGONISTS MINDRANK AI LTD. (CN) 2025-10-02 — — US disclosed
US-20250282757-A1 ARYL ETHER-SUBSTITUTED HETEROCYCLIC COMPOUNDS AS GLP1R AGONISTS MINDRANK AI LTD. (CN) 2025-09-11 — — US disclosed
CN-117242067-B Novel aryl ether substituted heterocycles as GLP1R agonists 杭州德睿智药科技有限公司 2025-03-25 — — CN disclosed
EP-4353717-A1 NOVEL ARYL ETHER SUBSTITUTED HETEROCYCLIC COMPOUND AS GLP1R AGONIST Mindrank AI Ltd. (CN) 2024-04-17 — — EP disclosed
US-20240067630-A1 ARYL ETHER-SUBSTITUTED HETEROCYCLIC COMPOUNDS AS GLP1R AGONISTS MINDRANK AI LTD. (CN) 2024-02-29 — — US disclosed
US-20240067630-A1 ARYL ETHER-SUBSTITUTED HETEROCYCLIC COMPOUNDS AS GLP1R AGONISTS MINDRANK AI LTD. (CN) 2024-02-29 — — US disclosed
US-20240067630-A1 ARYL ETHER-SUBSTITUTED HETEROCYCLIC COMPOUNDS AS GLP1R AGONISTS MINDRANK AI LTD. (CN) 2024-02-29 — — US disclosed
CN-117242067-A Novel aryl ether substituted heterocycles as GLP1R agonists 杭州德睿智药科技有限公司 2023-12-15 — — CN disclosed
US-20230121730-A1 OXADIAZOLINE COMPOUNDS OR SALTS THEREOF, AGROHORTICULTURAL FUNGICIDES CONTAINING THE COMPOUNDS, AND METHODS OF USING THE SAME NIHON NOHYAKU CO., LTD. (JP) 2023-04-20 — — US disclosed
WO-2023029380-A1 NOVEL ARYL ETHER SUBSTITUTED HETEROCYCLIC COMPOUND AS GLP1R AGONIST 杭州德睿智药科技有限公司 2023-03-09 — — WO disclosed
WO-2023010051-A1 PROTEIN SECRETION INHIBITORS GATE BIOSCIENCE, INC. (US) 2023-02-02 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12497384-B2 Aryl ether-substituted heterocyclic compounds as GLP1R agonists GLP1R, GIPR, GCGR L3MBTL1 3492/4885RAB9A 592/4885NPC1 1277/4885
US-12595249-B2 Aryl ether-substituted heterocyclic compounds as glpir agonists GLP1R, GIPR, GCGR L3MBTL1 1384/4885RAB9A 1015/4885NPC1 922/4885
US-20230121730-A1 OXADIAZOLINE COMPOUNDS OR SALTS THEREOF, AGROHORTICULTURAL FUNGICIDES CONTAINING THE COMPOUNDS, AND METHODS OF USING THE SAME CBR3, XDH, OXA1L L3MBTL1 555/4885RAB9A 2426/4885NPC1 4118/4885
US-20240067630-A1 ARYL ETHER-SUBSTITUTED HETEROCYCLIC COMPOUNDS AS GLP1R AGONISTS GLP1R, GIPR, GCGR L3MBTL1 3414/4885RAB9A 584/4885NPC1 1334/4885
US-20250304553-A1 ARYL ETHER-SUBSTITUTED HETEROCYCLIC COMPOUNDS AS GLP1R AGONISTS GLP1R, GIPR, GCGR L3MBTL1 3132/4885RAB9A 827/4885NPC1 690/4885
US-20250282757-A1 ARYL ETHER-SUBSTITUTED HETEROCYCLIC COMPOUNDS AS GLP1R AGONISTS GLP1R, GIPR, GCGR L3MBTL1 3779/4885RAB9A 563/4885NPC1 1393/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback